Back to Daily DR Market Summary

StreetAccount Summary - Asian Market Preview: Nikkei Futures +0.14%, Hang Seng Futures +0.82%, ASX SPI 200 +0.37%, S&P Futures (0.07%)

Nov 18 ,2024

  • Synopsis:

    • Asian markets set for positive start to Tuesday trade. Futures pointing to opening gains in Hong Kong and Japan. ASX higher in initial trade. S&P 500 futures flat afterhours. Australian and New Zealand bonds strengthening following latest stabilization in Treasury yields. FX markets steady following broad dollar pullback. Gold and crude rebounded from last week's heavy loss. Bitcoin fluctuating around $90K.

    • Dollar weakness the big story in FX markets after DXY pulled back from around two-year high. Comes after relentless run higher following Trump's election win as market moved to price in shallower Fed easing cycle amid dampened disinflation momentum. However, also gave rise to concerns dollar rally has become overstretched after speculative net long contracts reached highest since July.

    • No change in some of the other Asian market narratives. China equity underperformance in November tabbed to stimulus disappointment, economic weakness, and ramp trade/geopolitical tensions. Markets continue to weigh likely timing of next BOJ rate hike after Governor Ueda on Monday offered little in the way of clues. Asian FX weakness has stirred more intervention speculation.

  • Pre-open Company News:

    • 002352.CH -- S.F. Holding reports October revenue CNY24.10B vs year-ago CNY20.74B

    • 2522.HK -- Jiangxi Rimag Group CEO Chen Zhaoyang appointed as new chairman, effective today

    • 6098.HK -- Country Garden Services Holdings intends to buyback up to 334.3M shares under general mandate

    • 2222.AB -- Saudi Aramco, SINOPEC and Fujian Petrochemical break ground on new refining and petrochemical project in China

    • 7731.JP -- Nikon Corp downgraded to underperform from neutral at Mizuho Securities

    • 524494.IN -- Ipca Laboratories upgraded to accumulate from reduce at Prabhudas Lilladher

    • 9961.HK -- Trip.com Group reports Q3 non-GAAP EPADS CNY8.75 vs StreetAccount CNY6.93

    • 207940.KS -- Samsung Bioepis receives EC approval for aflibercept biosimilar OPUVIZ

    • 002653.CH -- Haisco Pharmaceutical Group's IND for HSK44459 tablets for treatment of Behçet disease accepted by NMPA

    • China Jan-Oct securities transaction stamp duty CNY86.6B, (46.4%) y/y

    • 008930.KS -- Hanmi Science Co. CEO Lim Jong-Hoon files complaint against CEO and external director of subsidiary Hanmi Pharmaceutical alleging embezzlement

    • 1810.HK -- Xiaomi reports Q3 adjusted net income CNY6.25B vs FactSet CNY5.96B

    • 000963.CH -- FDA approves Huadong Medicine's HDM1005 to clinical trial for treatment of MASH

    • 600884.CH -- Ningbo Shanshan chairman Zheng Ju, vice chairman Zhuang Wei resign, effective immediately

    • CC3.SP -- Street Takeaways - StarHub Q3 Business Update

  • On Deck:

    • Hong Kong:

      • Earnings:

        • ZTO Express (2057.HK)

    • Japan:

      • Earnings:

        • Sompo (8630.JP), MS&AD Insurance (8725.JP), Tokio Marine Holdings (8766.JP)

    • Australia:

      • Earnings:

        • WEB Travel Group (WEB.AU)

    • New Zealand:

      • Earnings:

        • Argosy Property (ARG.NZ)

  • Market Data:

    • Gold (Dec 24): +$2.00 or +0.08% to $2616.60

    • WTI Crude (Dec 24): ($0.18) or (0.26%) to $68.98

    • $-¥: +0.16 or +0.10% to 154.5030

    • $-KRW: (4.63) or (0.33%) to 1390.4700

    • A$-$: +0.00 or +0.63% to 0.6503

    • $-INR: (0.07) or (0.08%) to 84.4071

    • $-CNY: +0.01 or +0.08% to 7.2356

  • If you would like to receive the Asian Market Preview daily, please search for Asia Pre-Market Updates in Alert Manager.

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE